All News

acr_session2.jpeg

EULAR 2023 – Day 2 Report

Jack Cush, MD

Day 2 at the international EULAR Congress meeting is always bigger and busier. There were sessions on JIA therapies, crystal arthritis, novel drugs for SLE and Sjogren's, early RA and preclinical RA interventions, IgG4 disease, osteoporosis and the growth and application of artificial intelligence in medicine and rheumatology.

Read Article
question-mark-1872634_640.jpg

Better at Predicting RA from MRI: Humans or Computers?

David Liew, FRACP

An artificial intelligence model to assess pre-RA hand MRIs has confirmed what human readers have known before: that bone marrow edema and tenosynovitis are objectively the best predictors of future RA development in patients with clinically suspect arthralgias or undiffer

Read Article
Stills,continuum

AOSD: Young vs. Elderly Onset

Bella Mehta, MBBS, MS

Adult onset still's disease (AOSD) is an autoinflammatory condition characterized by fevers, arthritis, and rash. It is considered an orphan disease because of its low prevalence - it is reported anywhere between 16 to 40 per ten million.

Read Article
hip.THR_.jpg

EULAR 2023 – Day 1 Report

Jack Cush, MD

EULAR 2023 launched today to crowds of attendees.  The opening Plenary session and presidential address by Dr.

Read Article
arthritis.RA_.Xray_.hands_.jpg (keep)

An update on JAK inhibitors and cardiovascular risks

Antoni Chan, MD, PhD

In the last 2 years, there has been more caution and vigilance with the use of JAK inhibitors in the treatment of rheumatoid arthritis due to the risk of CV events, including MACE and VTE. The ORAL surveillance study, a post-approval safety study conducted in RA patients aged ≥50 years with ≥1 CV risk factor, has resulted in increased caution and greater emphasis on assessment of MACE and VTE risks in patients starting JAK inhibitors. 

Read Article
RheumNow Eular 2023 Daily Recap Series https://t.co/oZXuyv8wL5

Links:

Dr. John Cush RheumNow ( View Tweet)

Always great to have @EMA_News to come and to talk to us at #EULAR2023 Our meds are very important to us, and the more we can understand how decisions are made and RWE is collected, the better 👍 @RheumNow https://t.co/hSutraUsFD
David Liew drdavidliew ( View Tweet)
• Erdheim-Chester disease (ECD) is associated with Langerhans cell histiocytosis (LCH) • Bone pain, xanthelasma, hairy kidney • Differential diagnoses of LCH • BRAF mutation associated with cardiac and neurological phenotype of ECD Haroche J, Papo M #EULAR2023 @RheumNow https://t.co/AzKJKp82nq
Dr. Antoni Chan synovialjoints ( View Tweet)
Do we use too much PNL in GCA (when not using TCZ)? Could we wean quicker? Salvarini group n=22 26w PNL weaning protocol from GiACTA, but no TCZ 10/26 in relapse free remission at 1y Much less PNL, still some steroid AEs Way of the future for some? POS0728 #EULAR2023 @RheumNow https://t.co/qeZHeCi9vq
David Liew drdavidliew ( View Tweet)
You need to see this! Albert with a Left V1 distribution of #shingles is a ‘bot’ who interacts with #rheumatologists at #EULAR2023 ⁦@RheumNow⁩ ⁦@eular_org⁩ #artificial #intelligence https://t.co/gDwzc3NX7v
Janet Pope Janetbirdope ( View Tweet)
#EULAR2023 #POS0627 Researchers in Manchester identified several proteins associated with subclinical cardiovascular abnormalities on Cardiac MRI in Scleroderma using proteomics. Need validation. Could be useful for stratification and identify therapeutic targets @RheumNow https://t.co/55eNGhMu5f
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2023 #POS0618 This is cool! Researchers from Switzerland are developing new Quantitative Radiomic Risk Score (from HRCT) to stratify response to Anti-Fibrotic in #ILD. Data presented in pre-clinical study & paralleled molecular effects. Human study is in progress @RheumNow https://t.co/qAsWew4FEO
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Are we going to treat hands OA with MTX? Moderate effect on VAS pain at 6 and 12 months in a small RCT vs. PBO in hands OA WITH MRI detected synovitis. Thoughts 1) Is it really OA? 2) Benefit Risk balance remains debatable @RheumNow OP0070 #EULAR23 https://t.co/WLlX48NtGT
Aurelie Najm AurelieRheumo ( View Tweet)
#CPPD and #cervical involvement. Several clinical presentations A-asymptomatic deposition B-crowned dens syndrome C-retro-odontoid pseudotumor D-inflammatory discitis Good teaching points in the supplements! @RheumNow #EULAR2023 Abst#AB1859 https://t.co/LJe7Gk1oZX
Bella Mehta bella_mehta ( View Tweet)
#EULAR2023 #OP0007 What are the recent trends of autoimmune disease (AID)? A database study (22m) in UK showed: - 1 in 10 people had AID in the last 20yrs - socioeconomic, seasonal & regional disparities cd influence pathogenesis - CTD (SLE,pSS,SSc) tended to co-occur @RheumNow https://t.co/3DDPR2K5NC
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Colchicine 0.5mg BID for 12 weeks in #HandOA did not relieve pain. Results from 186 pts- double blind placebo controlled, randomized. MCID on VAS of 15 was not achieved. Presented at #EULAR2023 today abst#op0073 @RheumNow

Bella Mehta bella_mehta ( View Tweet)

EULAR PtoC management of targeted therapies in pts w/ IA & Hx cancer 1) If remission, initiate targeted therapy w/out delay 2) Prefer anti-cytokine bDMARDs if Hx solid cancer 3) B cell depleting therapy if Hx lymphoma 4) Use JAK inhibitors and abatacept with caution 🛑 https://t.co/cKhQVZwGh1
Aurelie Najm AurelieRheumo ( View Tweet)
Nathalie Conrad, Abstr#OP0007 @RheumNow presenting on the incidence, prevalence and co-occurrence of autoimmune disease - no evidence of overall increase in conditions. Environmental and socioeconomic factors involved in the presentation of the conditions https://t.co/3jy9NoltkG
Dr. Antoni Chan synovialjoints ( View Tweet)
Autoimmune disease diagnoses slowly on the rise, despite reduced smoking - but that’s now 10% of the population, & many patients have more than one. Most are lifelong. Surely this needs more investment?? CPRD data from the UK #EULAR2023 OP0007 @RheumNow https://t.co/7NGF5YaE9z https://t.co/m6SaibqmEq

Links:

David Liew drdavidliew ( View Tweet)
With all the benefits of MRI and expert rheumatologists, do our diagnoses of axSpA stick, two years later? Overwhelmingly yes, but sometimes we do actually have to change our minds. Beware the set and forget for our clinical diagnoses SPACE cohort #EULAR2023 OP0005 @RheumNow https://t.co/AN6XzqKlv3
David Liew drdavidliew ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×